It is a proud moment for George Clinical, India to collaborate with Project NIRAMAYA, a program for “Creation of Livelihood opportunities through Skill Development in the field of ‘Home Nursing’. In its two-fold agenda of providing sustainable healthcare support to the elderly with unmet needs in rural sectors, this program extends social and financial support […]
Read MoreThe 4th Annual Chronic Kidney Disease Drug Development (CKD3) Summit saw a select group of scientists, clinical researchers and experts from industry and regulatory agencies gathered face-to-face for the first time since the pandemic. Excitement and enthusiasm were evident as these experts networked and collaborated on how the latest scientific research is being applied to […]
Read MoreThe UPcare Group is now advancing to human trials with George Clinical with trials to begin soon. UPcare’s human trials are based on their previous pre-clinical and real-world data. Pre-clinical trial results conducted by The Doherty institute in 2020 indicated that compounds used in UPCare’s formulations and products are up to 99.99% effective at inhibiting […]
Read MoreOVERLAND PARK, KS., March 1, 2022 – George Clinical announces the expansion of its renal scientific leadership into Latin America with the addition of subject matter expert Hernán Trimarchi, MD, PHD, FACP, FASN. Dr. Trimarchi’s research focuses on glomerular diseases, particularly proteinuria and podocyturia, IgA nephropathy, focal segmental glomerulosclerosis, and Fabry disease. He is Head […]
Read MoreCOVID-19 propels clinical trial innovations from prolonged conjecture to a paradigm shift. Between March and November of 2020, COVID-19 negatively affected more than 1,200 clinical trials worldwide. Some were shut down completely while others were affected by lockdowns, patients becoming reluctant to continue with a trial or a host of other pandemic-related interruptions. As in […]
Read MoreExceptional kidney and metabolic scientific leadership network provides continuity, communication and cultural expertise in long-term global trial program. Background The National Institute of Diabetes and Digestive and Kidney Diseases (NIH) estimates that more than one in seven people with kidney disease have anemia, increasing their chance of developing heart problems and strokes. The prevalence […]
Read MoreSYDNEY, February 2, 2022 – George Clinical announces that the organization has been accredited by the Australian Office of the Gene Technology Regulator (OGTR) which allows it to be a licence holder for studies involving the use of genetically modified organisms (GMOs). The addition of this capability means that George Clinical can now, under the […]
Read MoreEight new pharmaceutical clinical trials with a value of more than $40 million are planned after the New South Wales government in Australia supported a joint venture between George Clinical and Guangzhou (China) based pharmaceutical company Link Health at the 28th biennial NSW-Guangdong Joint Economic Meeting. Minister for Trade and Industry Stuart Ayres said George […]
Read MoreBased on its recent analysis of the Asia-Pacific clinical contract research organization (CRO) industry, Frost & Sullivan recognizes George Clinical with the 2021 Asia-Pacific Competitive Strategy Leadership Award. As a leading APAC Clinical CRO company, George Clinical formulates solutions with innovation and scientific leadership to produce high-quality outcomes and maintain growth in the evolving CRO […]
Read MoreThe ASCEND program assessing the efficacy and safety of daprodustat for the treatment of anemia due to CKD across the CKD disease course is comprised of five Phase III studies. The program has enrolled over 8,000 patients who were treated for up to 4.26 years and spanned more than 35 countries. George Clinical was involved […]
Read More
